144. van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised con- trolled trial. Lancet. 2002;360:109 13. 145. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444 51. 146. Peverill RE, Harper RW, Smolich JJ. CARS trial: warfarin and thrombin generation: Coumadin Aspirin Reinfarction Study. Lancet. 1997;350: 1177 8. 147. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consid- eration of the extent of coronary artery disease and benefits of revascu- larization. J Am Coll Cardiol. 2004;43:585 91. 148. Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myo- cardial infarction. Circulation. 2009;120:2529 40. 149. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283 97. 150. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spon- taneous and iatrogenic hypoglycemia and mortality in patients hospi- talized with acute myocardial infarction. JAMA. 2009;301:1556 64. 151. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626 32. 152. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449 61. 153. Antman EM, Anbe DT, Armstrong PW, et al. 